Via Nova Therapeutics

Via Nova Therapeutics deploys state-of-the-art drug discovery modalities to identify novel, first-in-class antivirals for the individual infections they study. These modalities include phenotypic screening in infected cultured cells, biochemical screening in vitro on virus-encoded enzymatic targets and structure-based drug design, as well as combinations of the above approaches.